文献速递免疫规划传染病防控与疫情报告

BNT162b2和Ad26.COV2.S疫苗在南非Delta和Omicron时期对私人医疗保险计划成年会员COVID-19相关住院的有效性:一项检测阴性病例对照研究

Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
PubMed 文献 · Vaccine · 2025-04-02

该研究采用检测阴性病例对照设计,评估BNT162b2和Ad26.COV2.S疫苗在南非三个SARS-CoV-2变异时期对COVID-19相关住院的有效性。结果显示BNT162b2在所有变异时期均有保护作用,Delta时期VE为89.3%,Omicron BA.1降至31.4%,BA.4/5降至22.7%;Ad26.COV2.S的VE较低但仍有保护作用。≥60岁人群和HIV感染者均显示对重症感染的保护。

要点

  • BNT162b2对Delta住院VE为89.3%,对Omicron BA.1为31.4%,BA.4/5为22.7%。
  • Ad26.COV2.S对Delta住院VE为48.8%,对Omicron BA.1为19.8%,BA.4/5为45.0%。
  • ≥60岁人群和HIV感染者均显示对重症感染的保护。

核心结论

  • 疫苗接种对HIV感染者和老年人提供显著保护,是减少南非高危人群重症结局的有效手段。
  • 针对BA.4/5的疫苗有效性随时间推移而减弱,表明可能需要加强针。

研究设计与样本

  • 采用检测阴性病例对照设计,纳入私人医疗保险计划会员中因急性呼吸道感染住院的病例。
  • 研究时期为Delta(2021年5月9日至2021年9月18日)、Omicron BA.1(2021年11月28日至2022年2月5日)和BA.4/5(2022年4月17日至2022年5月28日)变异时期。
  • 所有数据包括疫苗接种史均从保险计划索赔中提取。
  • 使用逻辑回归模型计算疫苗有效性,调整年龄、合并症、接种后时间、收入水平和既往SARS-CoV-2感染记录。

主要发现

  • BNT162b2对COVID-19相关住院在所有变异时期均有保护作用:Delta期VE 89.3%(95%CI 85.9-91.9),Omicron BA.1期降至31.4%(95%CI 19.1-41.9),BA.4/5期降至22.7%(95%CI 2.2-38.9)。
  • Ad26.COV2.S的VE估计值虽低于BNT162b2,但在所有时期均有保护作用:Delta期48.8%(95%CI 39.6-56.5),Omicron BA.1期19.8%(95%CI 5.8-31.6),BA.4/5期45.0%(95%CI 29.8-57.0)。
  • 在≥60岁人群和较年轻年龄组中,以及HIV感染者和HIV未感染者中,均显示对重症感染的保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 vaccine effectiveness estimates from Africa are limited. These data can guide decisions on selecting priority groups in vaccine programs. This study estimated VE for BNT162b2 and Ad26.COV2.S against COVID-19-related hospitalisation, stratified by age group, time since vaccination, and HIV-infection status for three SARS-CoV-2 surges in South Africa. METHODS: We applied a test-negative case-control design to hospitalisations for acute respiratory infections amongst members of a medical insurance plan during the delta (9 May 2021-18 September 2021), omicron BA.1 (28 November 2021-5 February 2022), and BA.4/5 (17 April 2022-28 May 2022) variant periods. All data, including vaccination history, were extracted from insurance plan claims. Logistic regression models adjusted for age, comorbidities, time since vaccination, income level and documentation of previous SARS-CoV-2 infection, were used to calculate VE. RESULTS: BNT162b2 was protective against COVID-19-related hospitalisation for all variant periods (VE 89.3 % (95 % CI, 85.9-91.9) for delta, reduced to 31.4 % (95 % CI, 19.1-41.9) and 22.7 % (95 % CI, 2.2-38.9) for omicron BA.1, and BA.4/5 respectively). VE estimates for Ad26.COV2·S, although lower than BNT162b2, were protective for all periods (48.8 % (95 % CI, 39.6-56.5), 19.8 % (95 % CI, 5.8-31.6), and 45.0 % (95 % CI, 29.8-57.0) for delta, omicron BA.1, and BA.4/5 respectively). Protection against severe infection was shown in those ≥60 years and younger age groups, as well as in people living with HIV (PLWH) and HIV-uninfected individuals. CONCLUSION: Vaccination offered significant protection against COVID-19-related hospitalisation in PLWH and the elderly, and is therefore an effective means of reducing severe outcomes in these high-risk populations in South Africa. VE against BA.4/5 waned with time since vaccination suggesting boosters may be necessary.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Johnstone SL, Shapiro D, Chiwandire N, et al. Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study. Vaccine. 2025. PMID: 40180820. doi:10.1016/j.vaccine.2025.127068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。